Caregen Co., Ltd.
Price Chart
Key facts
- Market Cap
- ₩1.51T
- P/E
- 68.5x
- P/B
- 6.48x
- ROE
- 9.2%
Caregen Co., Ltd.
No description on file.
- CEO
- 정용지
- Employees
- 0
- Website
- caregen.co.kr
No description on file.
| Fiscal year | Revenue | Operating income | Net income | Operating margin |
|---|---|---|---|---|
| 2025 | ₩72.81B | ₩20.40B | ₩20.10B | 28.0% |
| 2024 | ₩82.59B | ₩34.25B | ₩32.31B | 41.5% |
| 2023 | ₩79.21B | ₩40.38B | ₩39.93B | 51.0% |
| 2022 | ₩69.10B | ₩33.63B | ₩27.22B | 48.7% |
In addition, companies such as K-Bio Labs, Aribio Lab, OptiPharm, iGene, SK Bioscience, HLB Genex, Macrogen, CJ Bioscience, Caregen, Biosmart, Qureatis, Synergy Innovation, Kukjeon, Earth Holdings, CT Bio, and SV Investment...
pinpointnewsNov 3, 2026
Among them, in the KOSDAQ market, six stocks saw price increases of over 5%, including Sapharon (+8.56%), HLB PEP (+7.09%), HLB Life Science (+6.98%), Green Cross Wellbeing (+6.89%), HLB Panajin (+6.51%), and L&C Bio (+5.85%). On the other hand, Caregen (-16.59%)...
newsmpNov 2, 2026
Ngen Bio, HLB Genex, Caregen, Korea Biotech, BC World Pharma, Chaperon, Jin Systems, Aptabio, Macrogen, Hyundai Bio, Inbiogen, Dreamtech, Pharmicell, Rigakem Bio, Inventis Lab, Biosmart, Genomic Tree, SV Investment...
pinpointnewsOct 29, 2026
Sources: Financials from DART filings, as filed. Prices and analyst consensus from licensed data providers. Latest annual results: fiscal 2025, period ended . Not investment advice. DART filings · How this data is collected · Report an error
On the other hand, Caregen, Celltrion Pharmaceutical, Genexine, HLB Therapeutics, HK Inno.N, and Hanmi Pharmaceutical are showing weakness. Inventis Lab, Lapaas, HLB Pharmaceuticals, Curatis, and Synergy Innovation, which are developing long-acting drug delivery technologies, are also under selling pressure. Recent stock prices...
pinpointnewsOct 29, 2026
Caregen, a peptide-based business, and Novaex, a health supplement manufacturer, are also showing weakness. Gradient and Seohung have recorded declines as well. Raw material and ingredient-related companies Jongkundang Bio and S&D, along with the bio business DXVX, are also...
pinpointnewsOct 20, 2026